BioMarin Pharmaceutical Inc. $BMRN Holdings Increased by Edmond DE Rothschild Holding S.A.

Edmond DE Rothschild Holding S.A. lifted its position in shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report) by 3.8% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 712,880 shares of the biotechnology company’s stock after purchasing an additional 25,850 shares during the period. Edmond DE Rothschild Holding S.A.’s holdings in BioMarin Pharmaceutical were worth $42,773,000 at the end of the most recent reporting period.

Several other large investors have also modified their holdings of BMRN. Parkside Financial Bank & Trust grew its holdings in shares of BioMarin Pharmaceutical by 70.3% during the second quarter. Parkside Financial Bank & Trust now owns 453 shares of the biotechnology company’s stock valued at $26,000 after buying an additional 187 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. bought a new position in shares of BioMarin Pharmaceutical in the second quarter worth approximately $39,000. Keating Financial Advisory Services Inc. purchased a new stake in BioMarin Pharmaceutical in the second quarter worth $56,000. Root Financial Partners LLC bought a new position in BioMarin Pharmaceutical in the 3rd quarter worth about $88,000. Finally, Parallel Advisors LLC raised its holdings in shares of BioMarin Pharmaceutical by 33.9% in the first quarter. Parallel Advisors LLC now owns 1,768 shares of the biotechnology company’s stock valued at $100,000 after acquiring an additional 448 shares in the last quarter. Institutional investors own 98.71% of the company’s stock.

BioMarin Pharmaceutical Price Performance

BMRN stock opened at $61.42 on Friday. The business has a 50 day simple moving average of $58.42 and a 200-day simple moving average of $58.54. The company has a market capitalization of $11.90 billion, a P/E ratio of -614.20, a PEG ratio of 0.82 and a beta of 0.21. BioMarin Pharmaceutical Inc. has a twelve month low of $49.26 and a twelve month high of $70.98. The company has a current ratio of 2.44, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56.

BioMarin Pharmaceutical (NASDAQ:BMRN – Get Free Report) last issued its quarterly earnings results on Monday, November 2nd. The biotechnology company reported $0.23 earnings per share for the quarter, topping the consensus estimate of ($0.05) by $0.28. BioMarin Pharmaceutical had a positive return on equity of 5.58% and a negative net margin of 0.52%. The firm had revenue of $1.02 billion during the quarter, compared to the consensus estimate of $1.02 billion. During the same period last year, the company earned $0.12 earnings per share. The company’s revenue for the quarter was up 32.0% on a year-over-year basis. As a group, equities analysts anticipate that BioMarin Pharmaceutical Inc. will post 2.20 EPS for the current year.

Insider Activity at BioMarin Pharmaceutical

In other BioMarin Pharmaceutical news, EVP Gregory Friberg sold 5,147 shares of BioMarin Pharmaceutical stock in a transaction on Wednesday, November 18th. The shares were sold at an average price of $58.81, for a total transaction of $302,695.07. Following the sale, the executive vice president owned 42,585 shares in the company, valued at $2,504,423.85. The trade was a 10.78% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Insiders own 0.68% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the company. Morgan Stanley reduced their price target on BioMarin Pharmaceutical from $119.00 to $103.00 and set an “overweight” rating for the company in a report on Friday, November 13th. Stifel Nicolaus lowered their price target on shares of BioMarin Pharmaceutical from $70.00 to $66.00 and set a “hold” rating for the company in a report on Tuesday, November 3rd. Weiss Ratings downgraded shares of BioMarin Pharmaceutical from a “sell (d+)” rating to a “sell (d)” rating in a research report on Friday, September 18th. Wall Street Zen upgraded BioMarin Pharmaceutical from a “hold” rating to a “buy” rating in a report on Sunday, November 8th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of BioMarin Pharmaceutical in a research report on Tuesday, November 3rd. Three equities research analysts have rated the stock with a Strong Buy rating, fifteen have assigned a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $87.22.

View Our Latest Analysis on BMRN

BioMarin Pharmaceutical Company Profile

(Free Report)

BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing medicines for people with rare genetic diseases. Its work includes research, clinical development, manufacturing and distribution of therapies for conditions that often have limited treatment options. The company’s marketed treatments address disorders including phenylketonuria, mucopolysaccharidosis, late-infantile neuronal ceroid lipofuscinosis, achondroplasia and hemophilia A. Its products include Kuvan and Palynziq for phenylketonuria, Vimizim for Morquio A syndrome, Brineura for CLN2 disease, Voxzogo for achondroplasia and Roctavian for hemophilia A. Founded in 1997 and headquartered in San Rafael, California, BioMarin serves patients and healthcare providers in the United States and international markets, including Europe.

See Also

Want to see what other hedge funds are holding BMRN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for BioMarin Pharmaceutical Inc. (NASDAQ:BMRN – Free Report).

Institutional Ownership by Quarter for BioMarin Pharmaceutical (NASDAQ:BMRN)

Receive News & Ratings for BioMarin Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioMarin Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.